

Remarks

Applicants submit this paper and request entry of the amendments herein. Claims 1-25, are currently pending in the application. Claims 1, 4, 8-11, 13-20, and 23 have been amended, as described above. Please cancel claims 3, 24 and 25 before calculating the fee. No new matter has been introduced.

The Specification has been amended to introduce a reference to the provisional patent application from which the present application claims the benefit of priority.

Claims 1 and 4 have been amended to more particularly claim the applicants' invention. Claims 8-11, 13-20 and 22-23 have been amended to remove improper multiple dependencies. Claim 23 has been amended to correct an obvious spelling error. Claims 13-15 have also been amended to replace "I" with "1" to appropriately refer to a compound of "formula 1" in Claim 12 from which they depend. Basis for this amendment may be found, at the least, in the Specification on page 7 lines 10-16.

Applicants respectfully request prompt consideration and allowance of the claimed subject matter. If a telephone interview would be of assistance in advancing prosecution of the subject application, Applicants' undersigned attorney invites the Examiner to telephone him at the number provided.

Respectfully submitted,

/Arvie J. Anderson/

Arvie J. Anderson
Attorney for Applicants
Registration No. 45,263
Phone: 317-277-7217

Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288

September 1, 2006